Free Trial
→ Is President Trump Lying To You With This? (From Colonial Metals) (Ad) Buy XENE Stock  Free XENE Stock Alerts

Xenon Pharmaceuticals (XENE) Financials

Xenon Pharmaceuticals logo
$28.49 -0.97 (-3.29%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$28.67 +0.18 (+0.63%)
As of 07:54 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Xenon Pharmaceuticals

Annual Income Statements for Xenon Pharmaceuticals

This table shows Xenon Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Income / (Loss) Attributable to Common Shareholders		 -234 -182 -125 -77 -28 -40 -32 -31 -23 -16
Consolidated Net Income / (Loss)		 -234 -182 -125 -79 -29 -42 -34 -31 -23 -16
Net Income / (Loss) Continuing Operations		 -234 -182 -125 -79 -29 -42 -34 -31 -23 -16
Total Pre-Tax Income 		-238 -183 -125 -79 -29 -42 -35 -32 -23 -16
Total Operating Income		 -279 -214 -129 -79 -31 -43 -38 -33 -25 -9.36
Total Gross Profit		 0.00 0.00 9.43 18 32 6.83 -6.00 0.31 1.80 16
Total Revenue		 0.00 0.00 9.43 18 32 6.83 0.00 0.31 1.80 16
Operating Revenue		 0.00 0.00 9.43 18 32 6.83 - 0.31 1.80 16
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 6.00 0.00 0.00 0.00
Total Operating Expenses		 279 214 139 97 63 50 32 33 27 25
Selling, General & Admin Expense		 69 47 33 22 13 11 8.41 7.31 6.79 9.79
Research & Development Expense		 210 168 106 75 51 39 24 26 20 15
Total Other Income / (Expense), net		 41 31 3.89 0.11 2.20 1.20 3.52 0.48 1.82 -6.39
Interest & Investment Income		 42 28 8.71 0.47 2.28 2.35 1.22 0.48 0.50 0.54
Other Income / (Expense), net		 -1.06 3.75 -4.83 -0.36 1.40 0.28 3.70 0.00 1.32 -6.93
Income Tax Expense		 -4.09 -0.29 0.12 -0.01 -0.26 -0.02 -0.02 - - -
Net Income / (Loss) Attributable to Noncontrolling Interest		 0.00 0.00 -0.44 -1.80 -0.82 -1.57 -2.88 0.00 - -
Basic Earnings per Share		 ($3.01) ($2.73) ($2.06) ($1.77) ($0.81) ($1.54) ($1.63) ($1.71) ($1.48) ($1.10)
Weighted Average Basic Shares Outstanding		 77.89M 66.89M 60.54M 43.63M 34.54M 25.94M 19.43M 17.99M 15.49M 14.28M
Diluted Earnings per Share		 ($3.01) ($2.73) ($2.06) ($1.77) ($0.81) ($1.54) ($1.63) ($1.72) ($1.48) ($1.10)
Weighted Average Diluted Shares Outstanding		 77.89M 66.89M 60.54M 43.63M 34.54M 25.94M 19.43M 18.00M 15.49M 14.28M
Weighted Average Basic & Diluted Shares Outstanding		 76.54M 75.43M 63.04M 43.63M 34.54M 25.94M 19.43M 18.00M 17.94M 14.30M

Quarterly Income Statements for Xenon Pharmaceuticals

This table shows Xenon Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -69 -59 -58 -48 -44 -48 -49 -42 -37 -37
Consolidated Net Income / (Loss)		 -66 -63 -58 -48 -45 -48 -47 -42 -37 -37
Net Income / (Loss) Continuing Operations		 -66 -63 -58 -48 -45 -48 -47 -42 -37 -37
Total Pre-Tax Income 		-70 -63 -58 -48 -45 -49 -48 -41 -36 -38
Total Operating Income		 -77 -74 -69 -59 -54 -56 -56 -49 -43 -38
Total Operating Expenses		 77 74 69 59 54 56 56 49 43 38
Selling, General & Admin Expense		 18 17 19 15 13 13 12 9.54 8.50 8.83
Research & Development Expense		 59 57 50 44 41 43 44 40 35 29
Total Other Income / (Expense), net		 7.94 11 11 12 8.75 7.07 7.94 7.61 7.08 0.39
Interest & Investment Income		 9.42 10 11 11 8.69 6.98 6.52 5.42 4.46 3.07
Other Income / (Expense), net		 -1.48 0.24 0.01 0.17 0.06 0.08 1.42 2.19 2.61 -2.68
Income Tax Expense		 -3.85 -0.32 -0.33 0.41 -0.21 -0.16 -0.22 0.29 1.14 -0.59
Basic Earnings per Share		 ($0.83) ($0.81) ($0.75) ($0.62) ($0.65) ($0.73) ($0.72) ($0.63) ($0.59) ($0.57)
Weighted Average Basic Shares Outstanding		 77.89M 77.93M 77.67M 77.59M 66.89M 66.00M 65.86M 65.72M 60.54M 65.47M
Diluted Earnings per Share		 ($0.83) ($0.81) ($0.75) ($0.62) ($0.65) ($0.73) ($0.72) ($0.63) ($0.59) ($0.57)
Weighted Average Diluted Shares Outstanding		 77.89M 77.93M 77.67M 77.59M 66.89M 66.00M 65.86M 65.72M 60.54M 65.47M
Weighted Average Basic & Diluted Shares Outstanding		 76.54M 76.24M 75.76M 75.47M 75.43M 65.43M 64.15M 63.56M 63.04M 62.54M

Annual Cash Flow Statements for Xenon Pharmaceuticals

This table details how cash moves in and out of Xenon Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Change in Cash & Equivalents		 -5.93 91 -118 131 20 -43 48 3.39 -42 -13
Net Cash From Operating Activities		 -181 -151 -101 -70 -48 -4.71 -35 -29 -20 -18
Net Cash From Continuing Operating Activities		 -182 -151 -101 -70 -48 -4.71 -35 -29 -20 -18
Net Income / (Loss) Continuing Operations		 -234 -182 -125 -79 -29 -42 -34 -31 -23 -16
Consolidated Net Income / (Loss)		 -234 -182 -125 -79 -29 -42 -34 -31 -23 -16
Depreciation Expense		 2.56 2.06 1.41 0.91 0.64 0.43 0.59 0.65 0.86 1.04
Amortization Expense		 1.25 - 0.82 - 0.22 0.53 0.28 0.01 0.00 0.00
Non-Cash Adjustments To Reconcile Net Income		 43 24 23 11 6.23 2.54 -1.13 0.76 0.86 11
Changes in Operating Assets and Liabilities, net		 5.71 5.61 -1.28 -2.59 -26 33 0.03 0.56 1.71 -14
Net Cash From Investing Activities		 165 -111 -293 -247 -17 -66 -29 24 -48 10
Net Cash From Continuing Investing Activities		 165 -111 -293 -247 -17 -66 -29 24 -48 10
Purchase of Property, Plant & Equipment		 -3.08 -5.62 -2.89 -2.05 -2.64 -1.24 -0.51 -0.32 -0.28 -0.55
Purchase of Investments		 -532 -794 -551 -389 -229 -140 -77 -28 -48 0.00
Sale and/or Maturity of Investments		 700 688 261 145 215 76 49 53 0.00 11
Net Cash From Financing Activities		 12 354 278 448 86 28 112 7.07 24 0.28
Net Cash From Continuing Financing Activities		 12 354 278 448 86 28 112 7.07 24 0.28
Issuance of Common Equity		 12 353 278 448 103 28 103 0.18 24 0.28
Other Financing Activities, net		 0.05 0.04 0.71 - - - - - - -
Effect of Exchange Rate Changes		 -1.67 0.38 -2.48 -0.59 -0.59 0.41 - 0.75 1.89 -5.74

Quarterly Cash Flow Statements for Xenon Pharmaceuticals

This table details how cash moves in and out of Xenon Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 55 -49 78 -90 49 35 -4.96 12 -46 -266
Net Cash From Operating Activities		 -54 -51 -33 -43 -35 -48 -33 -34 -35 -30
Net Cash From Continuing Operating Activities		 -54 -52 -33 -43 -35 -48 -33 -34 -36 -30
Net Income / (Loss) Continuing Operations		 -66 -63 -58 -48 -45 -48 -47 -42 -37 -37
Consolidated Net Income / (Loss)		 -66 -63 -58 -48 -45 -48 -47 -42 -37 -37
Depreciation Expense		 0.63 0.67 0.66 0.60 -0.63 1.73 0.60 0.35 0.30 0.36
Amortization Expense		 2.11 - - - - - - - - -
Non-Cash Adjustments To Reconcile Net Income		 6.54 12 15 9.40 4.58 7.95 6.97 4.11 0.10 9.00
Changes in Operating Assets and Liabilities, net		 2.44 -1.23 9.76 -5.25 -0.46 -3.45 6.67 2.85 0.52 -2.61
Net Cash From Investing Activities		 99 1.98 111 -46 -240 54 28 47 -12 -234
Net Cash From Continuing Investing Activities		 99 1.98 111 -46 -240 54 28 47 -12 -234
Purchase of Property, Plant & Equipment		 -0.78 -0.59 -1.51 -0.19 -0.08 -1.20 -2.13 -2.21 -1.75 -0.39
Purchase of Investments		 -66 -164 -125 -177 -377 -147 -162 -108 -115 -295
Sale and/or Maturity of Investments		 166 167 237 131 137 202 192 157 105 61
Net Cash From Financing Activities		 12 - - 0.00 324 30 - 0.00 0.01 0.70
Net Cash From Continuing Financing Activities		 12 - - 0.00 324 30 - 0.00 0.01 0.70
Issuance of Common Equity		 12 - - 0.00 324 - - 0.00 277 -277

Annual Balance Sheets for Xenon Pharmaceuticals

This table presents Xenon Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Total Assets		 798 965 754 572 189 148 122 46 67 64
Total Current Assets		 635 645 600 559 182 145 121 45 66 61
Cash & Equivalents		 143 149 57 176 45 25 68 20 17 59
Short-Term Investments		 484 489 535 376 132 117 52 23 47 0.00
Accounts Receivable		 1.47 0.87 0.99 2.77 1.82 0.81 0.15 0.44 0.20 0.32
Prepaid Expenses		 6.89 6.01 7.23 4.48 2.96 2.70 1.88 0.72 1.33 1.90
Plant, Property, & Equipment, net		 10 9.65 6.50 4.47 3.55 1.66 0.99 1.07 1.40 1.99
Total Noncurrent Assets		 153 310 147 8.52 3.85 1.17 0.11 0.23 0.41 1.09
Long-Term Investments		 127 293 129 0.00 - - - - - -
Noncurrent Deferred & Refundable Income Taxes		 9.67 0.80 0.51 0.47 0.52 0.24 0.11 - - -
Other Noncurrent Operating Assets		 15 17 18 8.06 3.33 0.93 - 0.23 0.41 1.09
Total Liabilities & Shareholders' Equity		 798 965 754 572 189 148 122 46 67 64
Total Liabilities		 43 37 33 22 18 56 19 10 3.59 2.92
Total Current Liabilities		 36 27 23 14 15 43 4.12 4.08 3.59 2.78
Accounts Payable		 34 26 22 14 11 8.82 4.12 3.38 3.59 2.63
Other Current Liabilities		 1.37 1.30 0.49 0.61 0.27 0.17 - - - -
Total Noncurrent Liabilities		 7.65 9.60 9.95 7.65 3.05 12 15 6.10 0.00 0.13
Other Noncurrent Operating Liabilities		 7.65 9.60 9.95 7.65 3.05 0.74 - - - 0.13
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 755 928 721 550 171 92 103 36 64 61
Total Preferred & Common Equity		 755 928 721 550 171 92 103 36 64 61
Total Common Equity		 755 928 721 542 164 84 96 36 64 61
Common Stock		 1,656 1,593 1,207 901 443 335 304 210 208 182
Retained Earnings		 -899 -665 -483 -357 -278 -250 -208 -173 -143 -120
Accumulated Other Comprehensive Income / (Loss)		 -1.61 -0.08 -3.00 -0.99 -0.99 -0.99 -0.99 -0.99 -0.99 -0.99

Quarterly Balance Sheets for Xenon Pharmaceuticals

This table presents Xenon Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 836 884 919 671 685 720 776
Total Current Assets		 660 728 707 531 545 533 649
Cash & Equivalents		 88 137 59 100 65 70 103
Short-Term Investments		 566 585 641 427 475 458 535
Accounts Receivable		 0.94 0.85 0.83 0.81 2.12 2.22 2.48
Prepaid Expenses		 4.69 5.70 6.77 3.53 2.89 4.09 8.51
Plant, Property, & Equipment, net		 10 10 9.39 10 9.56 7.98 4.58
Total Noncurrent Assets		 166 146 202 130 131 179 122
Long-Term Investments		 149 129 186 112 113 160 114
Noncurrent Deferred & Refundable Income Taxes		 1.05 0.73 0.40 0.60 0.45 0.22 0.51
Other Noncurrent Operating Assets		 16 16 16 17 18 18 7.56
Total Liabilities & Shareholders' Equity		 836 884 919 671 685 720 776
Total Liabilities		 38 40 31 35 38 33 23
Total Current Liabilities		 30 31 22 25 28 22 16
Accounts Payable		 28 30 21 23 27 21 16
Other Current Liabilities		 1.39 1.35 1.32 1.25 1.22 1.19 0.00
Total Noncurrent Liabilities		 8.40 8.68 9.10 9.76 10 10 7.16
Other Noncurrent Operating Liabilities		 8.40 8.68 9.10 9.76 10 10 7.16
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 798 844 888 637 646 687 753
Total Preferred & Common Equity		 798 844 888 637 646 687 753
Total Common Equity		 798 844 888 637 646 687 753
Common Stock		 1,630 1,617 1,603 1,260 1,222 1,213 1,201
Retained Earnings		 -834 -771 -713 -620 -572 -524 -445
Accumulated Other Comprehensive Income / (Loss)		 1.34 -2.21 -1.77 -2.95 -3.30 -1.82 -2.96

Annual Metrics And Ratios for Xenon Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Xenon Pharmaceuticals' official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% -100.00% -48.83% -42.68% 371.02% 0.00% -100.00% -82.75% -88.43% -45.09%
EBITDA Growth		 -32.80% -58.07% -67.94% -170.09% 30.15% -24.23% -4.88% -40.99% -48.38% -215.68%
EBIT Growth		 -33.31% -56.98% -68.82% -165.35% 29.70% -23.86% -5.43% -38.61% -44.23% -230.88%
NOPAT Growth		 -30.48% -65.75% -63.49% -152.37% 26.90% -12.56% -16.78% -31.26% -165.11% -159.00%
Net Income Growth		 -28.48% -45.48% -58.94% -173.54% 30.67% -20.58% -12.35% -33.51% -45.99% -221.00%
EPS Growth		 -10.26% -32.52% -16.38% -118.52% 47.40% 5.52% 5.23% -16.22% -34.55% -133.54%
Operating Cash Flow Growth		 -20.04% -49.57% -45.36% -44.42% -920.87% 86.42% -20.88% -46.81% -8.09% -6,905.64%
Free Cash Flow Firm Growth		 -36.13% -57.38% -56.88% -18.13% -1,844.98% 110.81% -20.08% -50.02% 27.00% -265.17%
Invested Capital Growth		 117.00% -505.63% 141.82% 69.14% 83.33% -3,294.38% -7.32% -279.18% -110.28% 121.16%
Revenue Q/Q Growth		 0.00% 0.00% -28.37% -7.12% 6.00% 95.11% -100.00% -53.65% -61.26% -9.58%
EBITDA Q/Q Growth		 -9.62% -7.24% -12.41% -19.56% -3.59% -6.69% -2.19% -6.28% -11.07% -49.14%
EBIT Q/Q Growth		 -9.93% -6.55% -12.98% -19.41% -3.19% -6.57% -2.47% -6.12% -10.01% -45.64%
NOPAT Q/Q Growth		 -9.31% -5.09% -16.71% -17.76% -4.42% -7.92% -1.07% -8.63% -13.02% -39.24%
Net Income Q/Q Growth		 -9.81% -4.20% -10.42% -20.17% -3.40% -7.27% -1.45% -7.20% -9.88% -48.73%
EPS Q/Q Growth		 -6.36% -2.25% -5.64% -8.59% 8.99% -5.48% 6.32% -8.18% -15.63% -280.33%
Operating Cash Flow Q/Q Growth		 -15.81% -1.80% -16.92% -12.27% -216.13% 85.15% -1.18% -8.16% 2.86% -14.53%
Free Cash Flow Firm Q/Q Growth		 -13.16% -5.04% -17.43% -7.29% -199.77% 111.86% -3.22% -6.85% 8.98% 0.00%
Invested Capital Q/Q Growth		 109.09% -18.64% -22.96% -153.79% 36.64% -629.83% 8.20% -97.24% -34.62% 335.94%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 100.00% 100.00% 100.00% 100.00% 0.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% 0.00% -1,396.48% -425.49% -90.30% -608.92% 0.00% -10,262.06% -1,255.52% -97.94%
Operating Margin		 0.00% 0.00% -1,368.91% -428.45% -97.31% -627.02% 0.00% -10,474.28% -1,376.43% -60.10%
EBIT Margin		 0.00% 0.00% -1,420.06% -430.41% -92.97% -622.89% 0.00% -10,474.28% -1,303.44% -104.60%
Profit (Net Income) Margin		 0.00% 0.00% -1,328.95% -427.85% -89.65% -609.09% 0.00% -9,872.67% -1,275.49% -101.12%
Tax Burden Percent		 98.29% 99.84% 100.09% 99.99% 99.12% 99.94% 99.93% 95.66% 100.00% 100.00%
Interest Burden Percent		 85.04% 86.87% 93.50% 99.41% 97.29% 97.84% 100.52% 98.54% 97.86% 96.67%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,625.06% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,615.90% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,588.25% 0.00%
Return on Equity (ROE)		 -27.85% -22.12% -19.72% -21.87% -21.90% -42.60% -49.55% -61.51% -36.81% -23.54%
Cash Return on Invested Capital (CROIC)		 -39,634.18% 0.00% -12,756.74% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -847.57%
Operating Return on Assets (OROA)		 0.00% 0.00% -20.20% -20.85% -17.75% -31.49% 0.00% -57.35% -35.76% -21.53%
Return on Assets (ROA)		 0.00% 0.00% -18.91% -20.73% -17.12% -30.80% 0.00% -54.05% -34.99% -20.81%
Return on Common Equity (ROCE)		 -27.85% -22.12% -19.60% -21.40% -20.62% -39.23% -46.80% -61.51% -36.81% -23.54%
Return on Equity Simple (ROE_SIMPLE)		 -31.04% -19.66% -17.38% -14.34% -16.83% -45.22% -33.40% -85.45% -35.99% -25.81%
Net Operating Profit after Tax (NOPAT)		 -196 -150 -90 -55 -22 -30 -27 -23 -17 -6.55
NOPAT Margin		 0.00% 0.00% -958.24% -299.91% -68.12% -438.91% 0.00% -7,331.99% -963.50% -42.07%
Net Nonoperating Expense Percent (NNEP)		 -4.61% -3.94% -5.50% -6.47% -4.57% -10.10% -11.15% -15.65% -9.16% -12.89%
Return On Investment Capital (ROIC_SIMPLE)		 -25.90% -16.15% -12.53% - - - - - - -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 347.78% 119.15% 40.24% 158.19% 0.00% 2,351.45% 376.71% 62.82%
R&D to Revenue		 0.00% 0.00% 1,121.13% 409.30% 157.07% 568.82% 0.00% 8,222.83% 1,099.72% 97.27%
Operating Expenses to Revenue		 0.00% 0.00% 1,468.91% 528.45% 197.31% 727.02% 0.00% 10,574.28% 1,476.43% 160.10%
Earnings before Interest and Taxes (EBIT)		 -280 -210 -134 -79 -30 -43 -34 -33 -24 -16
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -277 -208 -132 -78 -29 -42 -33 -32 -23 -15
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 3.96 3.25 3.42 2.97 3.29 4.03 1.67 1.42 2.16 1.89
Price to Tangible Book Value (P/TBV)		 3.96 3.25 3.42 2.97 3.29 4.03 1.67 1.42 2.16 1.89
Price to Revenue (P/Rev)		 0.00 0.00 261.41 87.41 16.74 49.66 0.00 163.49 76.42 7.42
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 4,450.58 0.00 2,397.45 0.00 0.00 0.00 0.00 0.00 0.00 23.89
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 185.01 57.91 11.48 32.37 0.00 44.96 40.84 3.66
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 76.98 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.17 0.15 0.19 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.12 0.15 0.17 0.00 0.00
Financial Leverage		 -1.00 -1.00 -1.00 -1.01 -1.15 -1.18 -1.01 -1.01 -0.98 -1.07
Leverage Ratio		 1.05 1.04 1.04 1.06 1.28 1.38 1.21 1.14 1.05 1.13
Compound Leverage Factor		 0.89 0.91 0.98 1.05 1.24 1.35 1.22 1.12 1.03 1.09
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 14.45% 12.69% 15.92% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 4.32% 0.00% 1.64% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 10.13% 12.69% 14.28% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 1.41% 4.51% 7.19% 6.54% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 98.59% 95.49% 78.36% 80.77% 84.08% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.37 -0.45 -0.21 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 3.03 3.12 1.16 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.26 -0.45 -0.19 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -0.52 -0.56 -0.30 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 4.20 3.92 1.62 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -0.36 -0.56 -0.27 0.00 0.00
Altman Z-Score		 39.64 48.12 44.77 43.85 16.76 1.21 2.84 -3.53 20.07 21.66
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.61% 2.14% 5.87% 7.92% 5.55% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 17.85 23.65 26.44 39.03 12.30 3.34 29.46 10.98 18.31 21.88
Quick Ratio		 17.66 23.43 26.12 38.72 12.10 3.28 29.00 10.80 17.94 21.20
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -199 -146 -93 -59 -50 2.87 -27 -22 -15 -20
Operating Cash Flow to CapEx		 -5,898.83% -2,690.26% -3,490.95% -3,390.34% -1,824.95% -380.16% -6,848.92% -9,119.37% -7,013.26% -3,285.48%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 -34.04 2.00 -19.05 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 -32.69 -3.29 -24.91 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -34.48 -4.15 -25.27 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.01 0.05 0.19 0.05 0.00 0.01 0.03 0.21
Accounts Receivable Turnover		 0.00 0.00 5.03 8.04 24.41 14.17 0.00 0.97 7.00 58.78
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 1.72 4.60 12.34 5.15 0.00 0.25 1.06 6.98
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 1.60 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 72.56 45.40 14.95 25.76 0.00 374.39 52.13 6.21
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 228.19 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 72.56 45.40 14.95 25.76 0.00 374.39 52.13 6.21
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.50 -2.95 0.73 -1.74 -5.64 -34 -1.00 -0.93 -0.25 2.38
Invested Capital Turnover		 0.00 0.00 -18.63 -4.99 -1.63 -0.39 0.00 -0.53 1.69 -3.51
Increase / (Decrease) in Invested Capital		 3.46 -3.68 2.47 3.90 28 -33 -0.07 -0.68 -2.63 14
Enterprise Value (EV)		 2,234 2,083 1,745 1,068 369 221 63 14 74 57
Market Capitalization		 2,989 3,014 2,466 1,612 538 339 159 51 138 116
Book Value per Share		 $9.90 $14.18 $11.54 $10.51 $4.67 $3.26 $3.79 $2.00 $3.57 $4.25
Tangible Book Value per Share		 $9.90 $14.18 $11.54 $10.51 $4.67 $3.26 $3.79 $2.00 $3.57 $4.25
Total Capital		 755 928 721 550 171 108 118 43 64 61
Total Debt		 0.00 0.00 0.00 0.00 0.00 16 15 6.80 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 11 15 6.10 0.00 0.00
Net Debt		 -754 -931 -721 -552 -177 -126 -104 -37 -64 -59
Capital Expenditures (CapEx)		 3.08 5.62 2.89 2.05 2.64 1.24 0.51 0.32 0.28 0.55
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -27 -20 -14 -7.08 -10.00 -35 -2.09 -2.23 -2.06 -0.57
Debt-free Net Working Capital (DFNWC)		 600 618 578 545 167 106 117 41 62 58
Net Working Capital (NWC)		 600 618 578 545 167 101 117 41 62 58
Net Nonoperating Expense (NNE)		 39 33 35 24 6.93 12 7.87 7.90 5.63 9.20
Net Nonoperating Obligations (NNO)		 -754 -931 -721 -552 -177 -126 -104 -37 -64 -59
Total Depreciation and Amortization (D&A)		 3.81 2.06 2.22 0.91 0.86 0.95 0.87 0.66 0.86 1.04
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% -153.60% -38.38% -31.07% -515.76% 0.00% -716.72% -114.09% -3.64%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 6,122.49% 2,954.37% 519.19% 1,554.21% 0.00% 13,324.12% 3,443.65% 372.88%
Net Working Capital to Revenue		 0.00% 0.00% 6,122.49% 2,954.37% 519.19% 1,486.12% 0.00% 13,099.04% 3,443.65% 372.88%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($3.01) ($2.73) ($2.06) ($1.77) ($0.81) ($1.54) ($1.63) ($1.71) ($1.48) ($1.10)
Adjusted Weighted Average Basic Shares Outstanding		 77.89M 66.89M 60.54M 51.92M 35.81M 34.96M 19.43M 17.99M 15.49M 14.28M
Adjusted Diluted Earnings per Share		 ($3.01) ($2.73) ($2.06) ($1.77) ($0.81) ($1.54) ($1.63) ($1.72) ($1.48) ($1.10)
Adjusted Weighted Average Diluted Shares Outstanding		 77.89M 66.89M 60.54M 51.92M 35.81M 34.96M 19.43M 18.00M 15.49M 14.28M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($1.77) ($0.81) ($1.54) ($1.63) ($1.71) ($1.48) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 76.54M 75.43M 63.04M 43.63M 34.54M 25.94M 25.75M 18.00M 17.94M 14.40M
Normalized Net Operating Profit after Tax (NOPAT)		 -196 -150 -90 -55 -22 -30 -27 -23 -17 -6.55
Normalized NOPAT Margin		 0.00% 0.00% -958.24% -299.91% -68.12% -438.91% 0.00% -7,331.99% -963.50% -42.07%
Pre Tax Income Margin		 0.00% 0.00% -1,327.70% -427.88% -90.45% -609.43% 0.00% -10,320.90% -1,275.49% -101.12%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 -20.32 -29.66 -24.64 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 -14.89 -20.90 -19.10 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -22.11 -30.53 -25.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -16.68 -21.77 -19.47 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Xenon Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Xenon Pharmaceuticals' official financial filings.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -100.00% -100.00% -100.00% 0.00% -98.38%
EBITDA Growth		 -40.43% -35.09% -27.67% -25.31% -34.25% -33.19% -69.42% -131.88% -61.33% -160.65%
EBIT Growth		 -47.20% -32.08% -27.47% -25.64% -31.73% -36.27% -69.32% -129.35% -60.78% -159.46%
NOPAT Growth		 -44.29% -32.31% -24.23% -20.37% -23.92% -46.04% -83.49% -182.41% -74.45% -144.44%
Net Income Growth		 -46.81% -29.57% -22.05% -14.87% -19.65% -30.45% -52.32% -112.14% -46.28% -140.53%
EPS Growth		 -27.69% -10.96% -4.17% 1.59% -10.17% -28.07% -30.91% -80.00% -22.92% -58.33%
Operating Cash Flow Growth		 -53.63% -6.38% 1.63% -25.48% -0.20% -58.14% -96.95% -86.73% -70.59% -102.59%
Free Cash Flow Firm Growth		 -70.15% -36.55% -33.41% -46.22% -3.37% -25.51% -59.74% -107.34% -54.08% -47.99%
Invested Capital Growth		 117.00% -121.98% -14.21% 720.88% -505.63% -363.39% -134.56% -109.30% 141.82% 237.76%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -75.37%
EBITDA Q/Q Growth		 -4.73% -6.33% -17.43% -10.39% -0.74% -0.49% -15.26% -15.68% 0.05% -27.83%
EBIT Q/Q Growth		 -7.51% -6.29% -17.36% -9.76% 3.53% -2.58% -15.67% -15.08% 0.21% -27.45%
NOPAT Q/Q Growth		 -5.16% -6.62% -17.04% -9.96% 3.57% -0.11% -13.40% -13.20% -13.65% -25.77%
Net Income Q/Q Growth		 -4.61% -8.40% -20.85% -7.13% 7.67% -2.11% -13.74% -11.58% -0.66% -19.23%
EPS Q/Q Growth		 -2.47% -8.00% -20.97% 4.62% 10.96% -1.39% -14.29% -6.78% -3.51% -3.64%
Operating Cash Flow Q/Q Growth		 -6.33% -56.51% 24.32% -21.75% 26.37% -44.72% 3.46% -5.13% -16.21% -80.23%
Free Cash Flow Firm Q/Q Growth		 -18.86% -2.06% -8.20% -29.63% 4.61% 0.29% -18.59% 8.36% -15.82% -26.91%
Invested Capital Q/Q Growth		 109.09% 15.65% -389.82% 176.53% -18.64% 56.60% -1,475.55% -150.00% -22.96% 138.65%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -30,640.15%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -28,884.85%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -30,911.36%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -28,143.94%
Tax Burden Percent		 94.47% 99.49% 99.43% 100.87% 99.54% 99.68% 99.54% 100.70% 103.14% 98.44%
Interest Burden Percent		 88.07% 85.94% 84.32% 80.71% 83.80% 87.44% 87.96% 88.43% 89.04% 92.49%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,056,445.08%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,056,442.99%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2,055,911.46%
Return on Equity (ROE)		 -27.85% -29.75% -26.71% -23.95% -22.12% -25.19% -22.86% 0.00% -19.72% -533.61%
Cash Return on Invested Capital (CROIC)		 -39,634.18% 0.00% 0.00% -7,055.52% 0.00% 0.00% 0.00% 0.00% -12,756.74% -8,368.89%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -782.82%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -712.74%
Return on Common Equity (ROCE)		 -27.85% -29.75% -26.71% -23.95% -22.12% -25.19% -22.86% 0.00% -19.60% -529.50%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -26.75% -23.58% -21.25% 0.00% -27.50% -25.33% -21.46% 0.00% -15.08%
Net Operating Profit after Tax (NOPAT)		 -54 -52 -48 -41 -38 -39 -39 -34 -30 -27
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -20,219.39%
Net Nonoperating Expense Percent (NNEP)		 -1.36% -1.56% -1.27% -0.84% -0.87% -1.36% -1.18% -1.21% -1.11% -2.09%
Return On Investment Capital (ROIC_SIMPLE)		 -7.18% - - - -4.05% - - - -4.20% -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 6,688.64%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 22,296.21%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 28,984.85%
Earnings before Interest and Taxes (EBIT)		 -79 -73 -69 -59 -54 -56 -54 -47 -41 -41
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -76 -73 -68 -58 -54 -54 -54 -47 -40 -40
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 3.96 3.74 3.49 3.66 3.25 3.44 3.79 3.28 3.42 2.98
Price to Tangible Book Value (P/TBV)		 3.96 3.74 3.49 3.66 3.25 3.44 3.79 3.28 3.42 2.98
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 18,539.01 3,377.44 261.41 170.66
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 4,450.58 0.00 0.00 1,045.10 0.00 0.00 0.00 0.00 2,397.45 1,582.58
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 13,598.16 2,348.54 185.01 113.55
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.00 -1.01 -1.01 -1.00 -1.00 -1.00 -1.01 -1.00 -1.00 -1.00
Leverage Ratio		 1.05 1.05 1.05 1.04 1.04 1.04 1.04 1.04 1.04 1.04
Compound Leverage Factor		 0.92 0.90 0.89 0.84 0.87 0.91 0.92 0.92 0.93 0.96
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 40.47 46.20 43.64 61.80 48.65 37.44 37.67 40.73 45.18 59.45
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.61% 0.77%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 17.85 22.21 23.27 31.82 23.65 21.46 19.34 23.71 26.44 41.78
Quick Ratio		 17.66 22.06 23.09 31.52 23.43 21.32 19.24 23.53 26.12 41.23
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -58 -49 -48 -44 -34 -36 -36 -30 -33 -28
Operating Cash Flow to CapEx		 -6,945.72% -8,668.98% -2,158.45% -22,967.02% -45,385.90% -4,006.58% -1,557.48% -1,559.88% -2,016.55% -7,876.17%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.03
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.06 0.26 5.03 4.61
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.11 1.72 2.98
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 6,424.83 1,405.63 72.56 79.22
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 6,424.83 1,405.63 72.56 79.22
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.50 -5.53 -6.55 2.26 -2.95 -2.49 -5.74 -0.36 0.73 0.95
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 -0.03 0.38 -18.63 101.71
Increase / (Decrease) in Invested Capital		 3.46 -3.04 -0.82 2.62 -3.68 -3.43 -3.29 -4.28 2.47 1.63
Enterprise Value (EV)		 2,234 2,180 2,092 2,362 2,083 1,552 1,795 1,569 1,745 1,496
Market Capitalization		 2,989 2,983 2,943 3,247 3,014 2,191 2,447 2,256 2,466 2,248
Book Value per Share		 $9.90 $10.53 $11.18 $11.77 $14.18 $9.92 $10.17 $10.90 $11.54 $12.10
Tangible Book Value per Share		 $9.90 $10.53 $11.18 $11.77 $14.18 $9.92 $10.17 $10.90 $11.54 $12.10
Total Capital		 755 798 844 888 928 637 646 687 721 753
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -754 -803 -851 -885 -931 -639 -652 -687 -721 -752
Capital Expenditures (CapEx)		 0.78 0.59 1.51 0.19 0.08 1.20 2.13 2.21 1.75 0.39
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -27 -24 -25 -15 -20 -20 -23 -16 -14 -4.55
Debt-free Net Working Capital (DFNWC)		 600 630 697 685 618 506 516 511 578 634
Net Working Capital (NWC)		 600 630 697 685 618 506 516 511 578 634
Net Nonoperating Expense (NNE)		 11 11 9.55 6.60 7.16 9.48 8.52 7.39 7.06 10
Net Nonoperating Obligations (NNO)		 -754 -803 -851 -885 -931 -639 -652 -687 -721 -752
Total Depreciation and Amortization (D&A)		 2.75 0.67 0.66 0.60 -0.63 1.73 0.60 0.35 0.30 0.36
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -17,532.58% -2,422.60% -153.60% -34.52%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 391,255.30% 76,476.05% 6,122.49% 4,810.86%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 391,255.30% 76,476.05% 6,122.49% 4,810.86%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.83) ($0.81) ($0.75) ($0.62) ($0.65) ($0.73) ($0.72) ($0.63) ($0.59) ($0.57)
Adjusted Weighted Average Basic Shares Outstanding		 77.89M 77.93M 77.67M 77.59M 66.89M 66.00M 65.86M 65.72M 60.54M 65.47M
Adjusted Diluted Earnings per Share		 ($0.83) ($0.81) ($0.75) ($0.62) ($0.65) ($0.73) ($0.72) ($0.63) ($0.59) ($0.57)
Adjusted Weighted Average Diluted Shares Outstanding		 77.89M 77.93M 77.67M 77.59M 66.89M 66.00M 65.86M 65.72M 60.54M 65.47M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 76.54M 76.24M 75.76M 75.47M 75.43M 65.43M 64.15M 63.56M 63.04M 62.54M
Normalized Net Operating Profit after Tax (NOPAT)		 -54 -52 -48 -41 -38 -39 -39 -34 -30 -27
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -20,219.39%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -28,588.64%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Xenon Pharmaceuticals' Financials

When does Xenon Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, Xenon Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Xenon Pharmaceuticals' net income changed over the last 9 years?

Xenon Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$234.33 million in 2024, rising from -$15.75 million in 2015. The previous period was -$182.39 million in 2023. Check out Xenon Pharmaceuticals' forecast to explore projected trends and price targets.

What is Xenon Pharmaceuticals's operating income?
Xenon Pharmaceuticals's total operating income in 2024 was -$279.30 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $279.30 million
How has Xenon Pharmaceuticals revenue changed over the last 9 years?

Over the last 9 years, Xenon Pharmaceuticals' total revenue changed from $15.58 million in 2015 to $0.00 in 2024, a change of -100.0%.

How much debt does Xenon Pharmaceuticals have?

Xenon Pharmaceuticals' total liabilities were at $43.24 million at the end of 2024, a 17.2% increase from 2023, and a 1,383.2% increase since 2015.

How much cash does Xenon Pharmaceuticals have?

In the past 9 years, Xenon Pharmaceuticals' cash and equivalents has ranged from $17.10 million in 2016 to $175.69 million in 2021, and is currently $142.71 million as of their latest financial filing in 2024.

How has Xenon Pharmaceuticals' book value per share changed over the last 9 years?

Over the last 9 years, Xenon Pharmaceuticals' book value per share changed from 4.25 in 2015 to 9.90 in 2024, a change of 133.2%.


Related Companies

This page (NASDAQ:XENE) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...
Premier Gold Co | Sponsored
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...
Paradigm Press | Sponsored
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...
Crypto Swap Profits | Sponsored
3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsored
Trump Predicts Dollar Downfall
READ THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...
Augusta Precious Metals | Sponsored